December 2008
EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine. NIAID will provide EpiVax with $390,000 over two years for the proposed research.November 2008
EpiVax Profiled as "Tech Firm in RI to Watch"
EpiVax was profiled in an article for Xconomy, which lists five "firms to watch" in Rhode Island who have utilized innovative...
October 2008
EpiVax Receives Tech Citizenship Award from Mass High Tech
EpiVax, Inc. has been named as a recipient of the Mass High Tech's 8th Annual Tech Citizenship Awards, which honors...
Publication on “Tregitopes” in Blood Journal of October 2008
Dr. Annie De Groot, CEO of EpiVax is the lead author on an article highlighting key findings about the activation of natural regulatory T cells by IgG Fc–derived peptide, also known as Epi-13 or “Tregitopes.” These findings were published in the October 8 issue of the prestigious Blood, the medical journal published by the American Society of Hematology.September 2008
Dr. Annie De Groot, CEO, awarded YWCA 2008 Women of Achievement Award
She addresses healthcare concerns. Dr. Annie De Groot is CEO and founder of EpiVax, Inc.; co-chief editor and founder of Infectious Diseases in Corrections Report; scientific director and founder of GAIA Vaccine Foundation, and interim medical director and founding member of Clinica Esperanza/Hope Clinic. She designs new vaccines for diseases, offers healthcare in Providence and HIV care in Africa, and advocates for HIV care on a national/international level.EpiVax awarded $35K Montel Williams Foundation grant for multiple sclerosis research
The Montel Williams MS Foundation today announced a grant to Providence-based Epivax, Inc., the first biotech-related company to be awarded a grant from the foundation.EpiVax Recieves $600,000 NIH Grant to Further Research in Type 1 Diabetes
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop “Epi-13”, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans.January 2008
EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference
February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium...
October 2007
EpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural "regulatory" T cells
October 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received...
September 2007
EpiVax awarded $590,000 SBIR for Immunoinformatics-driven TB Vaccine
The National Institutes of Health, National Institute Of Allergy And Infectious Diseases awarded a grant in the amount of $590,912 to EpiVax, Inc....